You are here: Industry Insights > Akston

News List

Phase 2 Trials from Akston COVID-19 Vaccine Candidate americanpharmaceuticalreview
August 09, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.
Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine americanpharmaceuticalreview
August 06, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.
Akston Biosciences, Seppic Ink Commercial Supply Agreement contractpharma
July 30, 2021
Akston Biosciences, a developer of new classes of biologic therapeutics, has entered a commercial agreement with Seppic S.A., a supplier of specialty healthcare ingredients, for the supply of adjuvant for use in Akston’s COVID-19 Fc fusion protein ...
Akston Biosciences to Supply Seppic’s Adjuvant to Create Shelf-Stable COVID-19 Vaccine americanpharmaceuticalreview
July 22, 2021
announced a commercial agreement with Akston Biosciences Corporation Seppic S.A., a supplier of specialty healthcare ingredients, for the supply of adjuvant for use in Akston’s COVID-19 Fc fusion protein vaccine candidate, AKS-452.
Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine americanpharmaceuticalreview
April 14, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine candidate.